Cancer immunology research has increasingly focused on the complex interactions between oncogenic drivers, such as KRAS mutations, and the tumor ...

A new generation of personalized cancer vaccines is taking shape through the use of neoantigen-based dendritic cell (DC) ...

From cell-manufacturing laboratories to outpatient infusion facilities, health systems are rapidly adapting to a new kind of cancer treatment that demands individualized care, infrastructure and ...

As immunotherapy becomes a cornerstone of cancer treatment, some of the top U.S. cancer centers and health systems are accelerating research efforts to identify the biological mechanisms behind ...

Immune checkpoints are a normal part of the immune system. Their role is to prevent an immune response from being so strong ...

A stunning new study offers early evidence that COVID-19 vaccines might have a secret superpower: a precisely timed mRNA shot could help many cancer patients live longer.

Patients diagnosed with hepatocellular carcinoma have poor survival rates and few effective options for therapy. In this review article, researchers from China have summarized the latest findings on ...

A phase II trial of neoadjuvant docetaxel/5-FU/cisplatin in combination with prophylactic pegteograstim in unresectable, locally advanced nasal cavity/paranasal squamous cell carcinoma: KCSG HN18-07.

Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues.

TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, ...